⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8770047 | 0.78 | — | — | |
| SCHEMBL5986157 | 0.78 | — | — | |
| SCHEMBL972049 | 0.75 | — | — | |
| SCHEMBL5985939 | 0.72 | — | — | |
| SCHEMBL8769442 | 0.70 | — | — | |
| SCHEMBL971763 | 0.67 | — | — | |
| SCHEMBL8769739 | 0.67 | — | — | |
| SCHEMBL5985549 | 0.67 | — | — | |
| SCHEMBL5984536 | 0.67 | — | — | |
| SCHEMBL7043784 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 889 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7511077-B2 | Diamine calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2009-03-31 | — | — | US | claimed |
| WO-2009005839-A2 | COMPOUNDS AND METHODS OF USE | THE GOVERNMENT OF THE U.S.A. AS REPRESENTED BY THE SECRETARY OF THE DEPT. OF HEALTH & HUMAN SERVICE (US) | 2009-01-08 | — | — | WO | claimed |
| EP-1846365-A1 | DIAMINE CALCIUM CHANNEL BLOCKERS | Neuromed Pharmaceuticals, Ltd. (CA) | 2007-10-24 | — | — | EP | claimed |
| US-20060235050-A1 | Diamine calcium channel blockers | NUEROMED TECHNOLOGIES, INC. (CA) | 2006-10-19 | — | — | US | claimed |
| WO-2006084369-A1 | DIAMINE CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2006-08-17 | — | — | WO | claimed |
| US-6713634-B2 | SEROTONIN RECEPTOR ANTAGONIST | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2004-03-30 | — | — | US | claimed |
| WO-2024149093-A1 | GLUCOCORTICOID RECEPTOR AGONIST AND CONJUGATE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2024-07-18 | — | — | WO | disclosed |
| CN-111801833-B | Nonaqueous electrolyte and energy device using same | 三菱化学株式会社 | 2024-07-16 | — | — | CN | disclosed |
| WO-2024143452-A1 | 3-METHYL-1-BUTENE-BASED POLYMER, MANUFACTURING METHOD THEREFOR, RESIN COMPOSITION, PELLET, AND MOLDED ITEM | 株式会社クラレ | 2024-07-04 | — | — | WO | disclosed |
| US-12009482-B2 | Nonaqueous electrolytic solution and electrical storage device including the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2024-06-11 | — | — | US | disclosed |
| WO-2024114531-A1 | HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2024-06-06 | — | — | WO | disclosed |
| WO-2024114523-A1 | ANTIBODY-DRUG CONJUGATE, PREPARATION METHOD THEREFOR, AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2024-06-06 | — | — | WO | disclosed |
| WO-2024114318-A1 | DRUG LINKER COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2024-06-06 | — | — | WO | disclosed |
| US-4470986-A | ISCHEMIA, SHOCK, THROMBOSIS | CIBA-GEIGY CORPORATION (US) | 1984-09-11 | — | — | US | disclosed |
| US-4460777-A | THROMBOXANE SYNTHETASE INHIBITORS | CIBA-GEIGY CORPORATION (US) | 1984-07-17 | — | — | US | disclosed |
| EP-0107618-A1 | N-substituted-2-(1-imidazolyl)-indoles | CIBA-GEIGY AG (CH) | 1984-05-02 | — | — | EP | disclosed |
| US-4444775-A | ENZYME INHIBITORS | CIBA-GEIGY CORPORATION (US) | 1984-04-24 | — | — | US | disclosed |
| US-4436746-A | CARDIOVASCULAR DISORDERS | CIBA-GEIGY CORPORATION (US) | 1984-03-13 | — | — | US | disclosed |
| EP-0080154-A2 | N-substituted 2-pyridyl indoles, process for their preparation, pharmaceutical compositions containing them, and their therapeutical use | CIBA-GEIGY AG (CH) | 1983-06-01 | — | — | EP | disclosed |
| EP-0068386-A1 | Substituted imidazo(1,5-a)pyridines, process for their preparation and pharmaceutical preparations containing these compounds | CIBA-GEIGY AG (CH) | 1983-01-05 | — | — | EP | disclosed |